The KRAS inhibitor market was valued at USD 108 million in 2023. During the forecast period, the market is expected to garner a 5.5% CAGR. By 2034, the gold metalized market is expected to reach a valuation of USD 196 million.
| Report Attribute | Details |
|---|---|
| Estimated Market Value in 2023 | USD 108 million |
| Expected Market Value in 2024 | USD 115.2 million |
| Projected Forecast Value in 2034 | USD 196 million |
| Anticipated Growth Rate from 2024 to 2034 | 5.5% |
The market players in the global KRAS inhibitor market are aimed at developing investigational drug candidates for the mutant KRAS. A key player has developed MRTX1133 which is used for the inhibition of KRASG12D. This candidate holds a strong potential to be a first of its kind therapeutic.
The development of KRAS inhibitor based combination treatments presents an opportunity. Improved patient outcomes, increased tumor response rates, and synergistic benefits may result from combining KRAS inhibitors alongside other targeted treatments, immunotherapies, or traditional chemotherapeutic drugs.
Exploring and implementing these combination techniques might result in innovative therapy regimens with improved efficacy against KRAS-mutated tumors, addressing unmet medical needs and widening the therapeutic environment in oncology.
In 2019, the global KRAS inhibitor market was estimated to reach a valuation of USD 81.8 million, according to a report from Future Market Insights. The KRAS inhibitor market witnessed significant growth, registering a CAGR of 7.20% during the historical period, 2019 to 2023.
| Historical CAGR from 2019 to 2023 | 7.20% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 5.5% |
The development of covalent inhibitors that specifically target specific KRAS mutants is a significant development in the KRAS inhibitor market. Traditional inhibitors frequently fail to target KRAS due to its complex structure and dynamic activity.
Covalent inhibitors may provide improved selectivity and effectiveness by forming a solid, permanent connection with their target. With the potential to provide patients with KRAS-driven tumors with more effective treatment choices, these covalent inhibitors mark a substantial advancement in KRAS-targeted therapy.
Innovative Drug Delivery Technologies to Support Market Demand
The KRAS inhibitor market is being driven by the development of innovative medication delivery systems. These innovative delivery methods increase the bioavailability and targeted administration of KRAS inhibitors. This helps in boosting their effectiveness and lowering the possibility of negative side effects.
These advances, which overcome difficulties such as low solubility and quick clearance, pave the path for more effective KRAS inhibitor treatment, improving their clinical relevance and, eventually, aiding patients with KRAS-mutated malignancies.
Poor Bioavailability and Inactivity of Cancer Cells to Restrict the Market Growth
Few of the inhibitors have been proven to show poor bioavailability, which delays the absorption of drugs. For instance, ARS-853, one of the first KRAS inhibitors developed not only had a lower bioavailability but also a shorter metabolic plasma stability.
KRAS inhibitors can at times fail to target all the cancer cells at the same time. In such a situation, this can lead to proliferation of the cancer cells at a faster pace. Such factors can impede the market growth.
This section focuses on providing detailed analysis of two particular market segments for KRAS inhibitor, the dominant cancer type and the significant end user. The two main segments discussed below are the pancreatic cancer and cancer diagnostic centers.
| Cancer Type | Pancreatic Cancer |
|---|---|
| CAGR from 2024 to 2034 | 5.3% |
During the forecast period, the KRAS inhibitors are anticipated to be widely used for treating pancreatic cancer. Since KRAS mutations are present in almost 90% of pancreatic tumors, targeted medicines such as KRAS inhibitors provide a promising way to combat the illness.
These inhibitors have the ability to precisely target the abnormal signaling pathways caused by KRAS mutations, which may slow the development of tumors and increase patient survival rates. Their ability to effectively combat pancreatic cancers with KRAS mutations makes them an indispensable part of any therapy plans for pancreatic cancer in the future.
| End User | Cancer Diagnostic Centers |
|---|---|
| CAGR from 2024 to 2034 | 5.1% |
During the forecast period, the cancer diagnostic center will be utilizing the KRAS inhibitors widely. KRAS inhibitors are being widely used in cancer diagnostic centers to precisely identify patients with KRAS mutations, allowing for customized treatment methods.
Early diagnosis of these mutations is made easier by including KRAS inhibitor testing into diagnostic processes. This helps with prognostication as well as treatment decision-making, which ultimately improves patient outcomes and raises the standard of cancer care.
This section will go into detail on the KRAS inhibitor markets in a few key countries, including the United States, the United Kingdom, China, Japan and South Korea. This sector will lay emphasis on the various reasons that are propelling the growth of KRAS inhibitors in the below mentioned regions.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 5.7% |
| The United Kingdom | 6.5% |
| China | 6.2% |
| Japan | 7% |
| South Korea | 6.9% |
The United States KRAS inhibitor ecosystem is anticipated to gain a CAGR of 5.7% through 2034. For instance, researchers from AstraZeneca have discovered a new drug candidate, AZD4747, which shows promise in treating tumors with the KRAS G12C mutation.
This mutation limits the ability of the GTPase KRAS to hydrolyze GTP to the inactive GDP-bound state, resulting in the constitutive activation of downstream signaling pathways.
The AstraZeneca research team discovered AZD4747, a highly effective and selective KRAS G12C inhibitor, using a structure-based drug development approach. Drug potency, drug metabolism, and pharmacokinetics (DMPK) characteristics were all optimized for the drug candidate.
The KRAS inhibitor market in the United Kingdom is expected to expand with a 6.5% CAGR through 2034. The regional companies are forging partnerships with companies outside the United Kingdom to boost their oncology pipeline.
For instance, the United Kingdom based Biotech Company RedX Pharma announced that it has entered an agreement with Jazz Pharmaceuticals, based out of Ireland. This was done to transfer the preclinical KRAS inhibitor program's global rights.
Under the conditions of the agreement, Redx Pharma will provide JAZZ an upfront payment of $10 million. This will be in return for all rights, patents, and interests pertaining to its exclusive KRAS inhibitor program, which includes its pan- and G12D-specific KRAS compounds.
The KRAS inhibitor ecosystem in China is anticipated to develop with a 6.2% CAGR from 2024 to 2034. As part of its wider healthcare reforms, the Chinese government has actively promoted and invested in the biotechnology and pharmaceutical industries.
The government's goals with the Made in China 2025 plan as well as the Healthy China 2030 policy are to solve healthcare issues and improve domestic innovation capacities.
Funding research and development in fields like cancer therapeutics, including KRAS inhibitors, is part of this. The development and marketing of KRAS inhibitors in China might be expedited by government financing, favorable policies, along with regulatory reforms.
The KRAS inhibitor industry in Japan is anticipated to reach a 7% CAGR from 2024 to 2034. Japan has a thriving pharmaceutical sector, with several major companies engaged in the research and development of new drugs.
These companies have an abundance of knowledge and resources devoted to cancer and other medicinal research and innovation. Japanese pharmaceutical companies are investing in the research and development of KRAS inhibitors as potential treatments for different cancers, with an emphasis on precision medicine and customized therapy.
The South Korea KRAS inhibitor ecosystem is anticipated to expand with a 6.9% CAGR during the forecast period. The biotechnology sector in South Korea is expanding quickly, with a particular emphasis on developing innovative treatments for a range of diseases, including cancer.
The country boasts a robust biotech workforce with advanced skills and a robust research infrastructure. Investing in biotech firms and research institutes helps to discover new treatments, including KRAS inhibitors, which have the potential to cure malignancies caused by mutations in the KRAS gene.
Market players are experimenting with various kinds of KRAS inhibitors for better outcomes to treat cancer patients. Companies are drifting towards researching with two forms, KRASG12C inhibitor and KRASG12D Inhibitor.
For instance, Adagrasib, which Mirati is developing, is intended to specifically target the KRASG12C mutation and optimize inhibition by trapping the mutant protein in an irreversible state. Adagrasib is one of the company’s highly selective, investigational and potent oral small molecule therapy.
Preclinical research has demonstrated that adagrasib produced significantly stronger anti-tumor activity when combined with a wide variety of medicines, such as SHP2, PD-1, Pan-EGFR, CDK 4/6, and SOS1 inhibitors.
The objective of the market players is to maximize effectiveness and avoid treatment resistance. They also want to make sure that patients may benefit from these potentially helpful combination treatments for the duration of their therapy. The key players in this market include:
Key Developments
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.5% from 2024 to 2034 |
| Market value in 2024 | USD 115.2 million |
| Market value in 2034 | USD 196 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2019 to 2023 |
| Forecast Period | 2024 to 2034 |
| Quantitative Units | USD million for value |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Cancer Type, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Amgen; Boehringer Ingelheim; BridgeBio Pharma; Erasca; Innovent Biologics Inc.; Incyte; Mirati Therapeutics; Novartis; Jemincare; Cardiff Oncology Inc. |
| Customisation Scope | Available on Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 8: Latin America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 11: Western Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 12: Western Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 15: Eastern Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 20: East Asia Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 21: East Asia Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by End-User, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 13: Global Market Attractiveness by Cancer Type, 2024 to 2034
Figure 14: Global Market Attractiveness by End-User, 2024 to 2034
Figure 15: Global Market Attractiveness by Region, 2024 to 2034
Figure 16: North America Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 17: North America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 22: North America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 23: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 24: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 28: North America Market Attractiveness by Cancer Type, 2024 to 2034
Figure 29: North America Market Attractiveness by End-User, 2024 to 2034
Figure 30: North America Market Attractiveness by Country, 2024 to 2034
Figure 31: Latin America Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 32: Latin America Market Value (US$ Million) by End-User, 2024 to 2034
Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 37: Latin America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 40: Latin America Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 43: Latin America Market Attractiveness by Cancer Type, 2024 to 2034
Figure 44: Latin America Market Attractiveness by End-User, 2024 to 2034
Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 46: Western Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 47: Western Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 52: Western Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 55: Western Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 58: Western Europe Market Attractiveness by Cancer Type, 2024 to 2034
Figure 59: Western Europe Market Attractiveness by End-User, 2024 to 2034
Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 61: Eastern Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 62: Eastern Europe Market Value (US$ Million) by End-User, 2024 to 2034
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 73: Eastern Europe Market Attractiveness by Cancer Type, 2024 to 2034
Figure 74: Eastern Europe Market Attractiveness by End-User, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 76: South Asia and Pacific Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 77: South Asia and Pacific Market Value (US$ Million) by End-User, 2024 to 2034
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 88: South Asia and Pacific Market Attractiveness by Cancer Type, 2024 to 2034
Figure 89: South Asia and Pacific Market Attractiveness by End-User, 2024 to 2034
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 91: East Asia Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 92: East Asia Market Value (US$ Million) by End-User, 2024 to 2034
Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 97: East Asia Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 100: East Asia Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 101: East Asia Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 103: East Asia Market Attractiveness by Cancer Type, 2024 to 2034
Figure 104: East Asia Market Attractiveness by End-User, 2024 to 2034
Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 106: Middle East and Africa Market Value (US$ Million) by Cancer Type, 2024 to 2034
Figure 107: Middle East and Africa Market Value (US$ Million) by End-User, 2024 to 2034
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by End-User, 2019 to 2034
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034
Figure 118: Middle East and Africa Market Attractiveness by Cancer Type, 2024 to 2034
Figure 119: Middle East and Africa Market Attractiveness by End-User, 2024 to 2034
Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
The KRAS inhibitor market is expected to garner a 5.5% CAGR from 2024 to 2034.
By 2024, the global KRAS inhibitor market is likely to gain USD 115.2 million.
By 2034, the KRAS inhibitor market valuation is likely to reach a sum of USD 196 million.
The KRAS inhibitor industry in the United States is likely to garner a 5.7% CAGR during the forecast period.
The KRAS inhibitor will be widely used for the treatment of pancreatic cancer, along with an anticipated 5.3% CAGR through 2034.
The cancer diagnostic centers are likely to be the dominant end users of the KRAS inhibitor, with an expected 5.1% CAGR through 2034.
Explore Therapy Area Insights
KRAS Inhibitor Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
